Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 1
1957 1
1961 1
1964 1
1966 2
1968 2
1970 2
1971 4
1972 3
1974 1
1975 1
1978 1
1979 3
1980 2
1981 7
1982 9
1983 7
1984 6
1985 4
1986 8
1987 8
1988 8
1989 8
1990 15
1991 18
1992 7
1993 12
1994 14
1995 17
1996 21
1997 15
1998 35
1999 28
2000 25
2001 24
2002 25
2003 22
2004 37
2005 36
2006 36
2007 53
2008 45
2009 52
2010 47
2011 58
2012 51
2013 41
2014 57
2015 45
2016 57
2017 67
2018 65
2019 62
2020 64
2021 61
2022 31
Text availability
Article attribute
Article type
Publication date

Search Results

1,197 results
Results by year
Filters applied: . Clear all
Page 1
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. Among authors: yokoi t. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Free article. Clinical Trial.
Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis.
Nakahara Y, Hashimoto N, Sakamoto K, Enomoto A, Adams TS, Yokoi T, Omote N, Poli S, Ando A, Wakahara K, Suzuki A, Inoue M, Hara A, Mizutani Y, Imaizumi K, Kawabe T, Rosas IO, Takahashi M, Kaminski N, Hasegawa Y. Nakahara Y, et al. Among authors: yokoi t. Eur Respir J. 2021 Dec 23;58(6):2003397. doi: 10.1183/13993003.03397-2020. Print 2021 Dec. Eur Respir J. 2021. PMID: 34049947
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: yokoi t. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.
Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: yokoi t. Lung Cancer. 2021 Nov;161:26-33. doi: 10.1016/j.lungcan.2021.08.015. Epub 2021 Aug 31. Lung Cancer. 2021. PMID: 34500218
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Haratani K, Teraoka S, Tokito T, Murakami S, Tamiya A, Itoh S, Yokouchi H, Watanabe S, Yamaguchi O, Tomii K, Yamamoto N. Fujimoto D, et al. Among authors: yokoi t. Eur J Cancer. 2021 Jun;150:63-72. doi: 10.1016/j.ejca.2021.03.016. Epub 2021 Apr 20. Eur J Cancer. 2021. PMID: 33892408
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
Saito G, Oya Y, Taniguchi Y, Kawachi H, Daichi F, Matsumoto H, Iwasawa S, Suzuki H, Niitsu T, Miyauchi E, Yokoi T, Yokoyama T, Uenami T, Sakata Y, Arai D, Okada A, Nagata K, Teraoka S, Kokubo M. Saito G, et al. Among authors: yokoi t. Lung Cancer. 2021 Nov;161:86-93. doi: 10.1016/j.lungcan.2021.08.019. Epub 2021 Sep 5. Lung Cancer. 2021. PMID: 34543942
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ. Hui R, et al. Among authors: yokoi t. Lancet Oncol. 2019 Dec;20(12):1670-1680. doi: 10.1016/S1470-2045(19)30519-4. Epub 2019 Oct 7. Lancet Oncol. 2019. PMID: 31601496 Clinical Trial.
Models of Idiosyncratic Drug-Induced Liver Injury.
Yokoi T, Oda S. Yokoi T, et al. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:247-268. doi: 10.1146/annurev-pharmtox-030220-015007. Epub 2020 Sep 25. Annu Rev Pharmacol Toxicol. 2021. PMID: 32976738
Diagnosis and Treatment of Myopic Maculopathy.
Yokoi T, Ohno-Matsui K. Yokoi T, et al. Asia Pac J Ophthalmol (Phila). 2018 Nov-Dec;7(6):415-421. doi: 10.22608/APO.2018290. Epub 2018 Sep 26. Asia Pac J Ophthalmol (Phila). 2018. PMID: 30255668 Review.
Direct imaging of atomistic grain boundary migration.
Wei J, Feng B, Ishikawa R, Yokoi T, Matsunaga K, Shibata N, Ikuhara Y. Wei J, et al. Among authors: yokoi t. Nat Mater. 2021 Jul;20(7):951-955. doi: 10.1038/s41563-020-00879-z. Epub 2021 Jan 11. Nat Mater. 2021. PMID: 33432148
1,197 results